Brief: Eliem Therapeutics Reports Q3 Loss Of $0.37 Per Share

Climb Bio

14/11/2022 11:16

Nov 14 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL AND
BUSINESS
HIGHLIGHTS
    * CASH RUNWAY EXPECTED TO FUND OPERATIONS INTO 2025
    * POSITIONED TO INITIATE ETX-155 PHASE 2A TRIAL IN MAJOR
DEPRESSIVE DISORDER IN Q1 OF 2023 WITH 60-MILLIGRAM DOSE
    * PROGRESSING IND-ENABLING STUDIES FOR TWO KV7
PRE-CANDIDATES WITH
SAFETY STUDIES PLANNED IN Q1 OF 2023
    * QTRLY LOSS PER SHARE $0.37
    * Q3 EARNINGS PER SHARE VIEW $-0.43 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX4TqFg5 
Further company coverage:  ELYM.O 
 ((Reuters.Briefs@thomsonreuters.com;))